Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

被引：0
|
作者：
Faidon-Marios Laskaratos
Martin Walker
Keval Naik
Emmanouil Maragkoudakis
Nikolaos Oikonomopoulos
Lee Grant
Tim Meyer
Martyn Caplin
Christos Toumpanakis
机构：
[1] Centre for Gastroenterology,Department of Infectious Disease Epidemiology
[2] Neuroendocrine Tumour Unit,Department of Radiology
[3] Centre for Gastroenterology,undefined
[4] Royal Free Hospital NHS Foundation Trust,undefined
[5] School of Public Health,undefined
[6] Faculty of Medicine,undefined
[7] Imperial College London,undefined
[8] Royal Free Hospital NHS Foundation Trust,undefined
[9] UCL Cancer Institute,undefined
[10] University College London,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
octreotide LAR; neuroendocrine tumours; antiproliferative activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1321 / 1327
页数：6
相关论文
共 50 条
  • [11] Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin
    Jann, H.
    Denecke, T.
    Koch, M.
    Pape, U. F.
    Wiedenmann, B.
    Pavel, M.
    NEUROENDOCRINOLOGY, 2013, 98 (02) : 137 - 143
  • [12] Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
    Fazio, N.
    Granberg, D.
    Grossman, A.
    Saletan, S.
    Winkler, R. E.
    Panneerselvam, A.
    Wolin, E. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S463 - S463
  • [13] Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression
    Verslype, C.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2011, 74 (01): : 93 - 94
  • [14] Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors
    Saglam, Sezer
    Hacisahinogullari, Hulya
    Ozturk, Nakiye
    Kapran, Yersu
    Gulluoglu, Mine
    Turkmen, Cuneyt
    Adalet, Isik
    Bilge, Ali Orhan
    Balci, Numan Cem
    JOURNAL OF BUON, 2015, 20 (05): : 1201 - 1205
  • [15] Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: efficacy data in pNET and non-pNET patients: ITMO (Italian Trials in Medical Oncology) group
    Bajetta, E.
    Catena, L.
    Fazio, N.
    Pusceddu, S.
    Biondani, P.
    Giuffrida, D.
    Ricci, S.
    Aieta, M.
    Pucci, F.
    Bianco, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S594 - S594
  • [16] Predictive Factors for Survival in Patients With Advanced Small Bowel Neuroendocrine Tumours
    Toumpanakis, Christos
    Vlachou, Erasmia
    Ramakrishnan, Shashank
    Phillips, Edward
    Wilkins, Dominic
    Tuck, Alexander
    Gertner, Julian
    Garcia-Hernandez, Jorge
    Theocharidou, Eleni
    Caplin, Martyn
    GASTROENTEROLOGY, 2016, 150 (04) : S207 - S207
  • [17] Predictive Factors for Survival in Patients with Advanced Small Bowel Neuroendocrine Tumours
    Toumpanakis, C.
    Vlachou, E.
    Ramakrishnan, S.
    Phillips, E.
    Tuck, A.
    Wilkins, D.
    Gertner, J.
    Hernandez, J. G.
    Mullan, M.
    Theocharidou, E.
    Caplin, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 27 - 27
  • [18] (Neo-) Adjuvant and first-line therapy. Prognostic and predictive factors
    Lux, Michael P.
    Oenuegoeren, Onur
    Wunderle, Marius
    Hein, Alexander
    Rauh, Claudia
    Schrauder, Michael G.
    Fasching, Peter A.
    Beckmann, Matthias W.
    GYNAKOLOGE, 2015, 48 (12): : 876 - 884
  • [19] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [20] First-line therapy for advanced colorectal cancer
    de Gramont A.
    Tournigand C.
    Louvet C.
    Maindrault-Goebel F.
    André T.
    Current Oncology Reports, 2005, 7 (3) : 167 - 172
12345